News for Hepion Pharmaceuticals, Inc. (HEPA)

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of NKGen Biotech, Inc. N

MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (HEPA), a clinical stage biopharmaceutical company that is developing and com

Hepion Pharmaceuticals (HEPA) has announced the appointment of Kaouthar Lbiati as interim CEO, taking effect on June 16, 2025. She succeeds John Brancaccio, who

Dr. Kaouthar Lbiati appointed as interim CEO of Hepion Pharmaceuticals (OTC:HEPA) effective June 16, 2025. Hepion shifts focus to precision diagnostics,

Hepion Pharmaceuticals (HEPA) has disclosed that it will be delisted from the Nasdaq Stock Market following a decision by the Nasdaq Hearings Panel. The company

MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (HEPA), a clinical stage biopharmaceutical company that had been developing a

Hepion Pharmaceuticals (HEPA) receives delisting notification from Nasdaq due to compliance issues. The stock will be suspended on Nasdaq and transition

Pharma Two B's P2B001 shows promising results for early-stage Parkinson's patients. Hepion Pharmaceuticals Inc. (HEPA) has a significant upside potentia

Summary: Hepion Pharmaceuticals, Inc. (HEPA) is engaging in a significant public offering to raise approximately $9 million. The company's shares could s

Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc.

Shares of Intel Corporation INTC rose sharply in today's pre-market trading after the company announced a new chief executive officer. The company said its boa...

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.30%

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Wednesday. The Dow traded up 0.27% to 44,146.86 whi...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Wednesday. The Dow traded up 0.30% to 44,159.42 whil...

**media[521489]**

Hepion Pharmaceuticals launches $9 million stock offering

Hepion Pharmaceuticals, Inc. (HEPA) Wednesday announced a mutual decision to terminate the merger agreement with Rehovot, Israel-based Pharma Two B Ltd. The Edison, New Jersey-based clinical stage biopharmaceutical company said there would be no termination fee.

EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. ( HEPA) (the ”œCompany” or ”œHepion”), a clinical stage biopharmaceutical c

Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson's disease (PD) support P2B001 as a first